BEAMSTART Logo

Celltrion scraps merger with Celltrion Pharm

Korea Economic Daily LogoKorea Economic Daily3h ago

Celltrion scraps merger with Celltrion Pharm - Korea Economic Daily

Quick Summary:

Celltrion’s market capitalization stood to 42.8 trillion won, compared with 3.1 trillion won of Celltrion Pharm.By contrast, 67.7% of Celltrion Pharm shareholders voted in favor of the merger, saying the combined entity would grow into a full-fledged biotechnology company and create synergy in new drug development.Celltrion holds a 53.81% stake in Celltrion Pharm.

CONSULTANTS' VIEWS In addition to the shareholder survey, consulting companies that reviewed the proposed merger concluded that their combination would deteriorate Celltrion’s financial conditions and would likely cost more than it spent to purchase shares from shareholders opposing the merger between Celltrion and Celltrion Healthcare last year.

Celltrion said that 58% of the shareholders against their marriage claimed their estimated merger ratio would fail to reflect the company’s fair value, arguing Celltron Pharm is trading far above its corporate value.


More Pictures

Celltrion scraps merger with Celltrion Pharm - Korea Economic Daily (Picture 1)Celltrion scraps merger with Celltrion Pharm - Korea Economic Daily (Picture 2)

or

Article Details

Category: Economy

Markets:

Topics:

Source Website Secure: Yes (HTTPS)

News Sentiment: Neutral

Fact Checked: Legitimate

Article Type: News Report

Published On: 2024-08-16 @ 16:38:55 (3 hours ago)

News Timezone: GMT +8:00

News Source URL: kedglobal.com

Language: English

Article Length: 413 words

Reading Time: 3 minutes read

Sentences: 21 lines

Sentence Length: 20 words per sentence (average)

Platforms: Desktop Web, Mobile Web, iOS App, Android App

Copyright Owner: © Korea Economic Daily

News ID: 22096500

View Article Analysis

About Korea Economic Daily

Korea Economic Daily Logo

Main Topics: Economy

Official Website: kedglobal.com

Update Frequency: 15 posts per day

Year Established: 1964

Headquarters: South Korea

News Last Updated: 10 minutes ago

Coverage Areas: South Korea

Ownership: Independent Company

Publication Timezone: GMT +8:00

Content Availability: Worldwide

News Language: English

RSS Feed: Available (XML)

API Access: Available (JSON, REST)

Website Security: Secure (HTTPS)

Publisher ID: #91

Publisher Details

Frequently Asked Questions

How long will it take to read this news story?

The story "Celltrion scraps merger with Celltrion Pharm" has 413 words across 21 sentences, which will take approximately 2 - 4 minutes for the average person to read.

Which news outlet covered this story?

The story "Celltrion scraps merger with Celltrion Pharm" was covered 3 hours ago by Korea Economic Daily, a news publisher based in South Korea.

How trustworthy is 'Korea Economic Daily' news outlet?

Korea Economic Daily is a fully independent (privately-owned) news outlet established in 1964 that covers mostly economy news.

The outlet is headquartered in South Korea and publishes an average of 15 news stories per day.

It's most recent story was published 10 minutes ago.

What do people currently think of this news story?

The sentiment for this story is currently Neutral, indicating that people are not responding positively or negatively to this news.

How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.
  • News ID: #22096500
  • URL: https://beamstart.com/news/celltrion-scraps-merger-with-celltrion-17237946991

BEAMSTART

BEAMSTART is a global entrepreneurship community, serving as a catalyst for innovation and collaboration. With a mission to empower entrepreneurs, we offer exclusive deals with savings totaling over $1,000,000, curated news, events, and a vast investor database. Through our portal, we aim to foster a supportive ecosystem where like-minded individuals can connect and create opportunities for growth and success.

© Copyright 2024 BEAMSTART. All Rights Reserved.